伏美替尼治疗EGFR T790M突变非小细胞肺癌的2b期研究
这项在中国46家医院开展的单臂、开放标签2b期研究纳入220例EGFR T790M突变晚期非小细胞肺癌患者,口服伏美替尼80 mg每日一次。客观缓解率为74%(95%CI 68-80),≥3级不良事件发生率为26%,治疗相关≥3级不良事件为11%。伏美替尼显示出良好疗效和可接受的安全性。
要点
- 伏美替尼80 mg每日一次治疗EGFR T790M突变NSCLC的客观缓解率达74%。
- ≥3级不良事件发生率26%,治疗相关≥3级不良事件发生率11%。
- 常见治疗相关腹泻和皮疹均为1-2级。
核心结论
- 伏美替尼对EGFR T790M突变NSCLC显示出良好疗效和可接受的安全性。
- 伏美替尼有望成为中国人群一/二代EGFR TKI治疗后的新选择。
研究设计与样本
- 单臂、开放标签、2b期研究,在中国大陆46家医院开展。
- 220例经中心确认EGFR T790M突变的局部晚期或转移性NSCLC患者接受伏美替尼80 mg口服每日一次。
- 主要终点为客观缓解率,由盲法独立中心评审按RECIST 1.1评估。
主要发现
- 客观缓解率为74%(163/220,95%CI 68-80)。
- ≥3级不良事件发生于58例(26%),治疗相关≥3级不良事件发生于25例(11%)。
- 严重不良事件52例(24%),其中研究者判定可能治疗相关12例(5%)。
- 最常见全因≥3级不良事件包括γ-谷氨酰转移酶升高(5例,2%)等。
关键数值与推荐
- 客观缓解率74%(95%CI 68-80)。
- ≥3级不良事件发生率26%,治疗相关≥3级不良事件发生率11%。
- 治疗相关腹泻发生率5%,皮疹发生率7%,均为1-2级。
- 严重不良事件发生率24%,可能治疗相关严重不良事件发生率5%。
临床怎么用
- 伏美替尼80 mg每日一次可作为EGFR T790M突变NSCLC患者一/二代EGFR TKI进展后的治疗选择。
- 治疗期间需关注≥3级不良事件,尤其是γ-谷氨酰转移酶升高、肝酶升高、低钠血症、高血压、肺部感染等。
- 腹泻和皮疹多为1-2级,但仍需监测和管理。
局限性
- 单臂设计,无对照臂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met (T790M) mutations. This study aimed to assess the efficacy and safety of furmonertinib in patients with EGFR T790M mutated advanced non-small-cell lung cancer (NSCLC). METHODS: This study was a single-arm, open-label, phase 2b study at 46 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC with centrally confirmed EGFR T790M mutations in tumour tissue who progressed after first or second generation EGFR TKIs or with primary EGFR T790M mutations received furmonertinib 80 mg orally once daily. The primary endpoint was objective response rate. Efficacy was assessed by blinded independent central review as per the Response Evaluation Criteria in Solid Tumors (version 1.1) in all patients who had measurable disease at baseline and received at least one dose of furmonertinib. Safety was assessed as per the Common Terminology Criteria for Adverse Events (version 4.03) in all patients who received at least one dose of furmonertinib with at least one safety assessment during follow-up. This study is registered with ClinicalTrials.gov (NCT03452592) and is ongoing for survival follow-up. FINDINGS: From Jun 4, 2018, to Dec 8, 2018, 220 patients received furmonertinib treatment. All 220 patients were included in the efficacy and safety analyses. At the data cutoff point of Jan 29, 2020, 71 (32%) patients remained on treatment. The median duration of follow-up was 9·6 months (range 0·7-19·4). The objective response rate was 74% (163 of 220 [95% CI 68-80]). Grade 3 or higher adverse events occurred in 58 (26%) patients and treatment-related grade 3 or higher adverse events occurred in 25 (11%) patients. The most common all-cause grade 3 or higher adverse events were increased γ-glutamyltransferase (five; 2%), increased aspartate aminotransferase, increased alanine aminotransferase, hyponatraemia, hypertension, pulmonary infection, hypermagnesaemia, and pericardial effusion (three each; 1%). Treatment-related diarrhoea was reported in ten (5%) patients and rashes were reported in 16 (7%) patients, all grade 1-2. Serious adverse events were reported in 52 (24%) patients, of which 12 (5%) were possibly treatment-related as evaluated by the investigator. INTERPRETATION: Furmonertinib has promising efficacy and an acceptable safety profile for the treatment of patients with EGFR T790M mutated NSCLC. Furmonertinib is expected to become a new treatment option after first or second generation EGFR TKIs in the Chinese population. FUNDING: Shanghai Allist Pharmaceutical Technology, Ministry of Science and Technology of the People's Republic of China, and Chinese Academy of Medical Sciences. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Shi Y, Hu X, Zhang S, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021. PMID: 33780662. doi:10.1016/S2213-2600(20)30455-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。